SG2918 For Advanced Malignant Tumors

Advanced Malignant Tumors Clinical Trial

Official title: A Phase I Clinical Study to Evaluate the Safety Tolerability and Preliminary Efficacy of SG2918 in Subjects With Advanced Malignant Tumors

Status Recruiting

Clinical Trial Summary

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant Tumors who are refractory or resistant to standard therapy, or without available standard or curative therapy.

Clinical Trial Description

The study consists of dose escalation and dose expansion, the dose escalation will be performed in a standard 3+3 manner at the dose of 0.1mg/kg、0.5mg/kg、1 mg/kg、1.5mg/kg、2 mg/kg、2.5mg/kg and 3 mg/kg, and the dose expansion will be done in specific tumor types. Patients enrolled in the study will receive SG2918 treatment every three weeks (Q3W), until disease progression, intolerable toxicity or others, whichever occurs first. ;

Related Conditions & MeSH terms

• Advanced Malignant Tumors
• Neoplasms

• NCT number: NCT06167486
• Study type: Interventional
• Source: Hangzhou Sumgen Biotech Co., Ltd.
• Contact: Zhengbo Song, Docter
• Phone: 86-13857153345
• Email: songzb@zjcc.org.cn
• Status: Recruiting
• Phase: Phase 1
• Start date: December 26, 2023
• Completion date: December 28, 2026